Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H11N3O2.ClH |
| Molecular Weight | 253.685 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1=C(NC(=O)N1)C(=O)C2=CC=NC=C2
InChI
InChIKey=SOIWUULWQIKDHV-UHFFFAOYSA-N
InChI=1S/C11H11N3O2.ClH/c1-2-8-9(14-11(16)13-8)10(15)7-3-5-12-6-4-7;/h3-6H,2H2,1H3,(H2,13,14,16);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C11H11N3O2 |
| Molecular Weight | 217.2239 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Piroximone is a nonglycoside, noncatecholamine inotropic agent. In animal experiments, it has been shown to increase cardiac contractility by mechanisms unrelated to any known receptor, acting mainly by inhibition of type III phosphodiesterase. Piroximone also possesses direct vasodilatory properties in the arterial and venous vascular bed. Piroximone combines well-balanced vasodilator and inotropic properties which make it very useful for the management of congestive heart failure. Piroximone had been in phase II clinical trial for the treatment of heart failure. However, this research has been discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Hemodynamic effects and concentration-effect relationship of a graded infusion of piroximone in patients with severe heart failure. | 1993 Mar |
|
| Determination of piroximone in human plasma by high-performance liquid chromatography. | 1994 Oct |
|
| Pharmacokinetics of piroximone after oral and intravenous administration to patients with renal insufficiency. | 1995 Feb |
|
| Direct depressant effect of phosphodiesterase inhibitors on ATPase activity of rat cardiac myofibrils. | 1995 May |
|
| Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP. | 1995 May 26 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:22:43 GMT 2023
by
admin
on
Fri Dec 15 15:22:43 GMT 2023
|
| Record UNII |
55MSM9KE7O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23623017
Created by
admin on Fri Dec 15 15:22:43 GMT 2023 , Edited by admin on Fri Dec 15 15:22:43 GMT 2023
|
PRIMARY | |||
|
55MSM9KE7O
Created by
admin on Fri Dec 15 15:22:43 GMT 2023 , Edited by admin on Fri Dec 15 15:22:43 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |